Spondyloarthritis

Screening patients with psoriasis, uveitis or inflammatory bowel disease for spondyloarthritis could improve early diagnosis, but no existing screening tools are generalizable to all who are at risk, according to a scoping review.

In a Healio video exclusive, Gil Y. Melmed, MD, MS, highlights certain therapies that should be avoided or included in the management of patients with extraintestinal manifestations of inflammatory bowel disease.

Men with inflammatory joint diseases have more children and are less likely to be childless, compared with those without inflammatory joint diseases, according to data published in the Annals of the Rheumatic Diseases.

SAN DIEGO — In patients with chronic rheumatic inflammatory disease, those who continue TNF inhibition during pregnancy have similar obstetrical outcomes as those who cease treatment, according to data presented at ACR Convergence 2023.

SAN DIEGO — Approximately 75% of patients in rheumatoid arthritis remission who taper TNF inhibitors to withdrawal experience a flare within 3 years, according to data presented at ACR Convergence 2023.

Key details expressing arthralgia duration, morning stiffness or joint examination findings are often missing from rheumatology referral letters for inflammatory arthritis, according to data published in Rheumatology Advances in Practice.

Patients with axial spondyloarthritis who receive bimekizumab demonstrate sustained improvement through 52 weeks and a safety profile consistent with shorter trials, according to data published in the Annals of the Rheumatic Diseases.

A fully automated, machine learning model that predicts bone marrow edema in sacroiliac joint MRI could improve screening for spondyloarthritis and decrease diagnostic delay, according to data published in Arthritis & Rheumatology.

A new consensus definition for early axial spondyloarthritis indicates disease that has manifested symptoms for less than 2 years, according to a recommendation published in Annals of the Rheumatic Diseases.

Lower back pain remains the leading global cause of years lived with disability, while projections estimate that more than 800 million people will experience lower back pain by 2050, according to data published in The Lancet Rheumatology.